No Wires, No Limits: A Bold Leap in Cardiac Tech
'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN.
'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.'
Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle.
At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems.
'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.'
At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine.
Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes.
Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove.
As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs.
As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted.
As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Sports Research® Launches Sam's Club Exclusive in Tempe, Arizona
Bringing Premium Wellness to the Desert's Innovation Capital TEMPE, Ariz., Aug. 14, 2025 /PRNewswire/ — Sports Research®, a leader in premium health and wellness supplements, is proud to announce the exclusive in-store release of two of its most advanced products at Sam's Club in Tempe, Arizona. Following the Grand Opening on August 7, Tempe shoppers will be the first in the country to get these best-selling Sports Research formulations. Magtein® Magnesium L-Threonate – 120 ct: One of the most clinically researched forms of magnesium that's been shown to cross the blood-brain barrier and support cognitive function.* Organic Collagen Peptides – 34 servings: The World's First Organic Collagen Peptides® – a sustainable product that offers support for healthy hair, skin, nails and joints.* This launch represents more than a regional rollout, it's a bold new model for how science-driven wellness meets everyday access. Tempe consumers are effectively being handed the power to lead what's next for 600+ Sam's Clubs nationwide. 'We are excited to introduce Sports Research Products to the Sam's Club Member,' said Abid Shivji, VP of Business Development and Strategy at Sports Research. 'This collaboration reflects our shared commitment to innovation and quality, ultimately paving the way for more accessible wellness solutions for consumers nationwide.' This is the first time Sports Research products have launched exclusively at a Sam's Club, underscoring a broader strategy: to bring top quality, transparent wellness solutions to the warehouse channel, with one influential, health-conscious community at the forefront. 'Starting in Tempe, we're building momentum for national growth, one cart, one customer, one community at a time. This release is not just about new products, it's about celebrating a passion for the wellness culture in Arizona,' said Dr. Jamie Wemette, Wholesale Director at Sports Research. 'We're not just launching in Sam's Club. We're launching a new era in our Generation Wellness Movement: Legacy meets accessibility.' With premium ingredients, trusted sourcing, and quality formulations, Sports Research is committed to making wellness essentials that work for everyone. Whether you're a fitness enthusiast, a busy parent, a health professional, or someone just starting your wellness journey, the launch offers access to high-quality supplements typically reserved for specialty or online channels. The Tempe Sam's Club is now stocking these exclusive products in-store, with availability coming soon to and select clubs nationwide. * These Statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Sports Research Since 1980, Sports Research has been a family-owned company driven by a legacy of health. Starting with the breakthrough of its flagship product, Sweet Sweat, Sports Research has expanded to offer a diverse range of wellness solutions for all generations. At the heart of Sports Research is a commitment to quality, sourcing only the finest ingredients and materials from around the world. Many of these ingredients are backed by rigorous scientific research, reflecting the brand's dedication to efficacy and innovation. Sports Research empowers individuals to live their best lives with products they can trust. Discover the difference wisdom and quality make by exploring the full product lineup at For Sports Research media inquiries, interviews, or product samples, please contact: Sports Research Communications Team: communications@
Malaysian Reserve
5 hours ago
- Malaysian Reserve
QuidelOrtho Launches Certified Analyzer Program
Initiative to expand testing access to underserved U.S. communities SAN DIEGO, Aug. 13, 2025 /PRNewswire/ — QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost. 'Our mission is rooted in equipping our customers so they can deliver diagnostic excellence to patients,' said Audra Jones, Senior Vice President, North America, QuidelOrtho. 'By repurposing and rigorously certifying high-performing analyzers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities.' Each analyzer in the program undergoes a robust, multi-point certification process at QuidelOrtho's Rochester facility, including over 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. These analyzers undergo a comprehensive certification process to align with QuidelOrtho's established quality and performance criteria and include a 12-month warranty on service and support. The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System. The VITROS platforms are designed to support community labs running general chemistries, immunoassay tests and drugs of abuse screening. 'We're proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction,' added Jones. 'This program isn't just about affordability; it's designed to improve accessibility and access of diagnostic solutions for healthcare providers in underserved communities.' QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit and follow QuidelOrtho on LinkedIn, Facebook and X. About QuidelOrtho Corporation QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day. Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic. Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions. Investor Contact: Juliet Cunningham Vice President, Investor Relations IR@ Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications Media@
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection
New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing sequencing requirements by 10- to 100-fold to achieve ultrasensitive detection levels and enabling a cost-effective whole-genome approach High efficiency and simple WGS workflow, yielding greater than 20x coverage per ng of cfDNA, reducing the amount of input material required for MRD and other liquid biopsy applications New highly sensitive approach to tumor-informed MRD as well as tumor-naive MRD and monitoring settings, where matched tumor tissue is not available FREMONT, Calif., Aug. 14, 2025 /PRNewswire/ — Ultima Genomics, a developer and manufacturer of an innovative ultra-high throughput sequencing architecture, announced a new publication, made available today in bioRxiv, showing the ultra-sensitive single-nucleotide variant (SNV) detection capabilities of its ppmSeq™ technology, with error rates down to 8 x 10-8. Led by researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center, this pre-print also demonstrates ctDNA detection limits for ppmSeq which significantly extends beyond the limits of currently available MRD assays, while utilizing a simple whole genome sequencing workflow that requires 10- to 100-fold less sequencing coverage versus other error correction techniques. These researchers conclude that these key features make ppmSeq well suited for clinical applications where high accuracy is required for mutation identification, such as tumor informed and tumor agnostic MRD detection. 'With its unique combination of low-cost and high accuracy, ppmSeq marks a real breakthrough in sequencing technology,' said Dan A. Landau, MD, PhD, a core member at the New York Genome Center, and Professor of Medicine & Professor of Physiology and Biophysics at Weill Cornell Medicine. 'It opens new horizons in studying the somatic genome as a novel frontier in human genetics, and holds enormous promise for clinical applications, including sensitive detection of cancer residual disease.' While high-throughput sequencing has seen rapid adoption for genome-wide variant identification, distinguishing true biological variation in the form of SNVs from sequencing errors remains a key challenge. Traditional sequencing approaches are too error-prone for detection of low variant allele frequency variants and are blind to errors resulting from DNA degradation or damage during sample preparation. These challenges limit the ability of traditional NGS technologies to detect and identify rare variants, a feature which is important in emerging applications like MRD and somatic mosaicism. To increase the ability to detect rare variants, current NGS approaches often rely on error-correction techniques, such as duplex sequencing, which involves sequencing both strands of a DNA molecule to filter out errors identified by discordant strands caused by single-stranded damage. While this reduces SNV error rates for dual-stranded reads, singleton reads must be discarded for these methods. As such, these methods require massive over sequencing to reliably capture sufficient duplex molecules, making whole-genome duplex sequencing prohibitively expensive. In a Nature Methods paper published in 2025, researchers in the Landau Lab demonstrated the advantages identifying SNVs with Ultima's flow-based sequencing by synthesis technology versus conventional SBS chemistry. Researchers identified that the ultra-low error profiles of Ultima's flow-based sequencing chemistry presented a foundation on which to build error correction techniques using duplex sequencing that could potentially enable ultra-low ctDNA detection levels, meaningful for applications that require rare mutation detection like MRD. In this new bioRxiv paper, researchers from the same group utilized ppmSeq, a technology developed by Ultima and native to the Ultima platform, to further improve upon the previously published low SNV detection limits. Building on Ultima's ultra-low error, flow-based sequencing, ppmSeq encodes both strands of DNA molecules in a single sequencing read to enable up to part-per-ten million (10-7) accuracy (SNVQ70) for SNV calling. This exceptional accuracy provides extreme assay sensitivity for low frequency alleles while also requiring 10- to 100-fold less sequencing depth than other error correction techniques. Study showcases ppmSeq as a highly accurate, low-cost, high throughput method for dsDNA sequencing built on a simple WGS workflow with potential for robust clinical applications Researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center benchmarked ppmSeq assay performance and sensitivity against other technologies. Key findings demonstrate ppmSeq has: Ultrasensitive SNV detection capabilities. ppmSeq demonstrated ultrasensitive SNV detection with error rates down to 0.8 x 10-7 (0.8 parts-per-ten million) for gDNA and cell-free DNA. Superior dsDNA recovery rates and lower sequencing requirements. ppmSeq demonstrated superior double-stranded DNA (dsDNA) recovery rates, reducing sequencing requirements by 10- to 100-fold and enabling a cost-effective whole genome approach. Ability to sequence low-input samples. The ppmSeq workflow was shown to be highly efficient, yielding greater than 20x coverage per ng of cfDNA and reducing the amount of input material required. Researchers also tested the capabilities of ppmSeq in clinical applications by assessing circulating tumor DNA (ctDNA) detection for disease monitoring in cancer patients. Key findings include: Tumor-informed ctDNA detection down to one-in-ten million. ppmSeq enabled tumor-informed ctDNA detection of 10-5 across multiple cancers, and up to 10-7 in cancers with high mutation burden at 30x sequencing depth, which extends below the limits of current MRD assays. ctDNA detection capabilities in tumor-naive disease monitoring. ppmSeq identified disease-specific signal in plasma cell-free DNA without the need for a matched tumor. Together, these researchers conclude that ppmSeq is a highly accurate and cost-effective option for emerging clinical applications including tumor-informed MRD, tumor-naïve MRD and an opportunity to explore new whole-genome applications in cancer genomics, including somatic mosaicism. 'As a highly accurate, highly scalable WGS approach, ppmSeq can be a key building block for the next generation of tumor-informed and tumor-naive cancer monitoring applications' said Adam Widman, MD, a researcher and medical oncologist at Memorial Sloan Kettering Cancer Center and a co-author on the study. 'ppmSeq is a major step forward in high-accuracy sequencing,' said Charles Swanton, Deputy Clinical Director at The Francis Crick Institute. 'Its low error rate and high throughput could enable powerful new applications in liquid biopsy and beyond. This study showcases how ultra-low error, high-throughput sequencing with ppmSeq could transform applications in the field of MRD requiring very high accuracy — from bench to bedside.' Ultima's ppmSeq technology enables high-quality data and its published specifications provide part-per-million accuracy, or SNVQ60, for calling single nucleotide variants (SNVs). ppmSeq, designed for the UG 100 sequencing platform, is also compatible with the UG 100 Solaris Free workflow. Launched at AGBT 2025, the UG 100 Solaris workflows enabled an over 50% increase versus prior specifications in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications. It especially excels in applications like liquid biopsy that require extreme accuracy, and we are excited to see further validation of ppmSeq within the academic community,' said Gilad Almogy, CEO and Founder of Ultima Genomics. 'We believe that sensitivity, ease of workflow and low cost of ppmSeq will be transformational for applications requiring earlier detection such as MRD.' The full study, 'Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules' is now available in bioRxiv. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Media Contact Vikki Herrera for Ultima Genomics408-206-7009vikki@
